F Hoffmann-La Roche has given marketing and development rights of BRAF inhibitor vemurafenib to Chugai Pharmaceutical. The licensing deal allows Roche to get milestone payments from Chugai Pharma.Chugai Pharma intends to begin a Phase I clinical trial for BRAF mutation-positive metastatic melanoma in Japan in 2012.Vemurafenib is being co-developed under a 2006 license and collaboration agreement between Roche and Plexxikon, a member of the Daiichi Sankyo Group.
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access the Media Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
Related stories
News
Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings
Medication errors are a big problem in healthcare because...
News
How to Dispose of Pharmaceutical Waste
Proper pharmaceutical waste disposal is crucial for protecting our...
News
Semaglutide 101: What You Need to Know About This Game-Changing Medication
In the realm of modern medicine, breakthroughs are not...
Latest stories
Previous article
Next article
